KOD - NASDAQ
Kodiak Sciences Inc.
$33.87
-8.2%Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
At a Glance
Live Snapshotkod
Other Non-Cash Items
Last Annual Value
9.92M
3-Year CAGR
101%
5-Year CAGR
189%
10-Year CAGR
29%
Kodiak Sciences Inc. Competitors Analysis of Other Non-Cash Items
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Kodiak Sciences Inc. NASDAQ:KOD | 9.92M | N/A | 118.8% | 29.2% | |
 AnaptysBio, Inc. NASDAQ:ANAB | 12.31M | 17.6% | 44.9% | 61.0% | |
 Nurix Therapeutics, Inc. NASDAQ:NRIX | -10.23M | N/A | N/A | N/A | |
 BridgeBio Oncology Therapeutics Inc. NASDAQ:BBOT | 7.23M | 547.1% | 895.5% | N/A | |
 Tango Therapeutics, Inc. NASDAQ:TNGX | 1.20M | 72.3% | -2.0% | N/A | |
 EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT | -4.83M | N/A | N/A | N/A | |
 UroGen Pharma Ltd. NASDAQ:URGN | 4.59M | -26.3% | N/A | 5.3% | |
 Phathom Pharmaceuticals, Inc. NASDAQ:PHAT | 37.50M | 5.4% | 47.3% | N/A | |
 Xencor, Inc. NASDAQ:XNCR | -144.38M | N/A | N/A | N/A | |
 ProKidney Corp. NASDAQ:PROK | -1.70M | N/A | N/A | N/A |
Kodiak Sciences Inc. Fair Value Envelope
Related Guides
Continue your KOD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.